{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:33:23Z","timestamp":1792794803694,"version":"4.5.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["AN372\/29-1"],"award-info":[{"award-number":["AN372\/29-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["30-1"],"award-info":[{"award-number":["30-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto de Salud Carlos II","award":["PI19\/01695"],"award-info":[{"award-number":["PI19\/01695"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"RICORS","award":["RD21\/0005\/0030"],"award-info":[{"award-number":["RD21\/0005\/0030"]}]},{"name":"ERK-NET","award":["445703531"],"award-info":[{"award-number":["445703531"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The management of immunoglobulin A nephropathy, membranous nephropathy, lupus nephritis, anti-neutrophil cytoplasmic antibody\u2013associated vasculitis, C3 glomerulonephritis, autoimmune podocytopathies and other immune-mediated glomerular disorders is focused on two major treatment goals, preventing overall mortality and the loss of kidney function. Since minimizing irreversible kidney damage best serves both goals, the management of immune-mediated kidney disorders must focus on the two central pathomechanisms of kidney function decline, i.e., controlling the underlying immune disease process (e.g. with immunotherapies) and controlling the non-immune mechanisms of chronic kidney disease (CKD) progression. Here we review the pathophysiology of these non-immune mechanisms of CKD progression and discuss non-drug and drug interventions to attenuate CKD progression in immune-mediated kidney disorders. Non-pharmacological interventions include reducing salt intake, normalizing body weight, avoiding superimposed kidney injuries, smoking cessation and regular physical activity. Approved drug interventions include inhibitors of the renin\u2013angiotensin\u2013aldosterone system and sodium\u2013glucose cotransporter-2. Numerous additional drugs to improve CKD care are currently being tested in clinical trials. Here we discuss how and when to use these drugs in the different clinical scenarios of immune-mediated kidney diseases.<\/jats:p>","DOI":"10.1093\/ndt\/gfad069","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T07:03:29Z","timestamp":1684825409000},"page":"ii50-ii57","source":"Crossref","is-referenced-by-count":23,"title":["CKD therapy to improve outcomes of immune-mediated glomerular diseases"],"prefix":"10.1093","volume":"38","author":[{"given":"Hans-Joachim","family":"Anders","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine IV, Hospital of the Ludwig-Maximilians-University , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema M","family":"Fernandez-Juarez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario La Paz , IdiPaz, Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Vaglio","sequence":"additional","affiliation":[{"name":"Department of Experimental and Biomedical Sciences \u201cMario Serio\u201d , University of Florence, Florence, Italy"},{"name":"Nephrology Unit, Azienda Ospedaliera Universitaria Meyer IRCCS , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Romagnani","sequence":"additional","affiliation":[{"name":"Department of Experimental and Biomedical Sciences \u201cMario Serio\u201d , University of Florence, Florence, Italy"},{"name":"Nephrology Unit, Azienda Ospedaliera Universitaria Meyer IRCCS , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Clinical Immunology, RWTH Aachen University Hospital , Aachen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"2024040807505052500_bib1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/S0140-6736(05)66583-X","article-title":"Glomerulonephritis","volume":"365","author":"Chadban","year":"2005","journal-title":"Lancet"},{"key":"2024040807505052500_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"2024040807505052500_bib3","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1177\/0961203313518625","article-title":"The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients","volume":"23","author":"Alvarado","year":"2014","journal-title":"Lupus"},{"key":"2024040807505052500_bib4","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2024040807505052500_bib5","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/ndt\/gfaa329","article-title":"SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, \u2018diabetic nephropathy\u2019, IgA nephropathy and podocytopathies with FSGS lesions","volume":"37","author":"Anders","year":"2022","journal-title":"Nephrol. Dial. Transplant"},{"key":"2024040807505052500_bib6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/annrheumdis-2021-221474","article-title":"Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors","volume":"81","author":"S\u00e4emann","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024040807505052500_bib7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.kint.2021.04.002","article-title":"SGLT-2 inhibition in IgA nephropathy: the new standard of care?","volume":"100","author":"Barratt","year":"2021","journal-title":"Kidney Int"},{"key":"2024040807505052500_bib8","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"2024040807505052500_bib9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2215\/CJN.12991117","article-title":"Glucocorticoids in the treatment of glomerular diseases: pitfalls and pearls","volume":"13","author":"Ponticelli","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024040807505052500_bib10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of ckd: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2024040807505052500_bib11","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2024040807505052500_bib12","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.2007090970","article-title":"Role of remission clinics in the longitudinal treatment of CKD","volume":"19","author":"Ruggenenti","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2024040807505052500_bib13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2024040807505052500_bib14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024040807505052500_bib15","doi-asserted-by":"crossref","first-page":"17088","DOI":"10.1038\/nrdp.2017.88","article-title":"Chronic kidney disease","volume":"3","author":"Romagnani","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2024040807505052500_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41581-021-00510-7","article-title":"Nephron overload as a therapeutic target to maximize kidney lifespan","volume":"18","author":"Luyckx","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2024040807505052500_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.kint.2022.02.039","article-title":"Current kidney function parameters overestimate kidney tissue repair in reversible experimental kidney disease","volume":"102","author":"Klinkhammer","year":"2022","journal-title":"Kidney Int"},{"key":"2024040807505052500_bib18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1681\/ASN.2014030278","article-title":"A potential role for mechanical forces in the detachment of podocytes and the progression of CKD","volume":"26","author":"Kriz","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2024040807505052500_bib19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-022-00559-y","article-title":"Glomerular hyperfiltration","volume":"18","author":"Cortinovis","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2024040807505052500_bib20","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1111\/bph.15734","article-title":"The mineralocorticoid receptor in chronic kidney disease","volume":"179","author":"Barrera-Chimal","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2024040807505052500_bib21","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/apha.12047","article-title":"Mechanisms of renal NaCl retention in proteinuric disease","volume":"207","author":"Svenningsen","year":"2013","journal-title":"Acta Physiol"},{"key":"2024040807505052500_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ccl.2019.04.001","article-title":"Cardiorenal syndrome: pathophysiology","volume":"37","author":"Kumar","year":"2019","journal-title":"Cardiol Clin"},{"key":"2024040807505052500_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1681\/ASN.2021091257","article-title":"Secondary immunodeficiency related to kidney disease (SIDKD)\u2014definition, unmet need, and mechanisms","volume":"33","author":"Steiger","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2024040807505052500_bib24","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/jch.13408","article-title":"High sodium intake increases blood pressure and risk of kidney disease. From the Science of Salt: a regularly updated systematic review of salt and health outcomes (August 2016 to March 2017)","volume":"20","author":"Malta","year":"2018","journal-title":"J Clin Hypertens"},{"key":"2024040807505052500_bib25","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/nu10060732","article-title":"Dietary salt restriction in chronic kidney disease: a meta-analysis of randomized clinical trials","volume":"10","author":"Garofalo","year":"2018","journal-title":"Nutrients"},{"key":"2024040807505052500_bib26","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature11868","article-title":"Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells","volume":"496","author":"Kleinewietfeld","year":"2013","journal-title":"Nature"},{"key":"2024040807505052500_bib27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/MNH.0000000000000727","article-title":"Treatment options for managing obesity in chronic kidney disease","volume":"30","author":"Parvathareddy","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2024040807505052500_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2024040807505052500_bib29","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1007\/s00467-021-04967-3","article-title":"L-type calcium channel blocker use and proteinuria among children with chronic kidney diseases","volume":"36","author":"Richardson","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"2024040807505052500_bib30","doi-asserted-by":"crossref","first-page":"e100835","DOI":"10.1371\/journal.pone.0100835","article-title":"Smoking is a risk factor for the progression of idiopathic membranous nephropathy","volume":"9","author":"Yamaguchi","year":"2014","journal-title":"PLoS One"},{"key":"2024040807505052500_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12882-021-02453-4","article-title":"Cigarette smoking may accelerate the progression of IgA nephropathy","volume":"22","author":"Wang","year":"2021","journal-title":"BMC Nephrol"},{"key":"2024040807505052500_bib32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1053\/j.ajkd.2006.08.023","article-title":"Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study","volume":"48","author":"Levey","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2024040807505052500_bib33","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"2024040807505052500_bib34","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"key":"2024040807505052500_bib35","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","volume":"68","author":"Remuzzi","year":"2005","journal-title":"Kidney Int"},{"key":"2024040807505052500_bib36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2024040807505052500_bib37","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/ndt\/gfab335","article-title":"Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial","volume":"37","author":"Wheeler","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2024040807505052500_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"2024040807505052500_bib39","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"key":"2024040807505052500_bib40","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.2215\/CJN.08900722","article-title":"Estimated lifetime benefit of combined RAAS and SGLT2 inhibitor therapy in patients with albuminuric CKD without diabetes","volume":"17","author":"Vart","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024040807505052500_bib41","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2024040807505052500_bib42","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"2024040807505052500_bib43","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2024040807505052500_bib44","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"De Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2024040807505052500_bib45","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/MNH.0000000000000716","article-title":"Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease","volume":"30","author":"Smeijer","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2024040807505052500_bib46","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int"},{"key":"2024040807505052500_bib47","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","article-title":"Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis","volume":"97","author":"Malvar","year":"2020","journal-title":"Kidney Int"},{"key":"2024040807505052500_bib48","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","article-title":"The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients","volume":"106","author":"Lim","year":"2022","journal-title":"Transplantation"},{"key":"2024040807505052500_bib49","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfad069\/51300690\/gfad069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/Supplement_2\/ii50\/57178738\/gfad069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/Supplement_2\/ii50\/57178738\/gfad069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T03:55:29Z","timestamp":1712548529000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/38\/Supplement_2\/ii50\/7176070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":49,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2023,5,22]]},"published-print":{"date-parts":[[2023,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfad069","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,5,22]]}}}